Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/682863


Competitor Analysis: CD20 Antibodies


Description: The present Competitive Intelligence Report about anti-CD20 antibodies used to treat B-cell mediated malignancies and rheumatoid arthritis provides a competitor evaluation in the field of R&D projects with anti-CD20 antibodies as of January 2009.

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are still clinically evaluating new autoimmune indications such as lupus nephritis, multiple sclerosis and vasculitis.

The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies (mabs) with improved properties compared with the chimeric antibody rituximab. At present, at least nine different anti-CD20 antibodies are in clinical development by competitors of rituximab and by Genentech & Roche themselves (to defend the rituximab market). At least further seven molecules are in preclinical development or pre-IND stage.

Improved anti-CD20 antibodies aim at reducing immunogenicity and the related side effects (infusion and anaphylactic reactions) by fully human or humanized antibodies. Other approaches target at increasing efficacy by binding to different epitopes on the B cell or increasing binding of the mab to the receptor or lowering the off-rate of the mab which results in prolonged presence on the B cell. Furthermore, effector functions are tried to be increased via antigen-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) or increased recruitment of T cells and accessory cells.
Development of subcutaneous instead of the currently used intravenous formulations of the mab may increase convenience of antibody administration. Other engineered anti-CD20 antibodies have reduced CDC to avoid infusion reactions, or are of small size to allow better tissue penetration. One of the next generation anti-CD20 molecules is being developed as a genotype-stratified, tailored therapy, thereby improving outcomes of the therapy by this personalized medicine approach.

The report includes a compilation of marketed products and current active projects in research and development of anti-CD20 antibodies. In addition, the report lists company-specific R&D pipelines of anti-CD20 antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category/Therapeutic Area,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


Contents: - CD20 Antibodies in Oncology
- CD20 Antibodies in Inflammation
- CD20 Antibodies in Neurology
- CD20 Antibodies in Hematology
- Corporate CD20 Antibody R&D Pipelines and Product Portfolios


Companies Mentioned - Bayer Schering Pharma - Biocon - Biogen Idec - BioLex - Cell Therapeutics - Dr. Reddy’s - Eli Lilly - Favrille - Fresenius Biotech - Genentech & Roche - Genmab - GlaxoSmithKline - GTC Biotherapeutics - Immunomedics - InNexus Biotechnology - LFB Biotechnologies - MacroGenics - Nanogen Biopharmaceuticals - Nycomed - Spectrum Pharmaceuticals - TRION Pharma - Trubion Pharmaceuticals - Wyeth


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/682863

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 12/02/2012 18:41:56
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Competitor Analysis: CD20 Antibodies
Web Address:
http://www.researchandmarkets.com/reports/682863
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €200.00
Electronic (PDF) - Site License €400.00
Electronic (PDF) - Enterprisewide €600.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 12/02/2012 18:41:56

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)